We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Fluid Monitor Aids Clinical Assessment of Lymphedema

By HospiMedica International staff writers
Posted on 09 Feb 2016
A novel monitoring system utilizes bioimpedance spectroscopy (BIS) to accurately measure tissue composition and fluid status.

The L-Dex U400 is designed to aid in the evaluation of unilateral lymphedema in arms by measuring certain characteristics of electrical resistance in the extracellular fluid present in a patient’s limb. More...
The results are delivered on a numeric scale, providing an instant and accurate tool for clinical assessment of lymphedema progression, as well as a way to track changes in the patient over time. The technology, which is specific for extracellular fluid, is unaffected by changes in the patient’s weight due to changes in fat mass or muscle mass, and can detect lymphedema up to 10 months before there is evidence of limb swelling.

The device can store more than 1,000 data records, which can be analyzed directly on the device or downloaded via an Ethernet connection to proprietary unilateral lymphedema analysis software installed on a Windows PC. To perform a measurement, three color-coded leads and dual-tab electrodes are placed on the patient, with measurements carried out by following on-screen instructions. Results appear on-screen and can be uploaded for storage or additional analysis. The L-Dex U400 is a product of ImpediMed (Brisbane, Australia), and has been approved by the US Food and Drug Administration (FDA).

“Fluid monitoring is a critical component in the continuum of care for cancer survivors. L-Dex is an accurate measurement tool, which can help improve health outcomes for patients through earlier identification of lymphedema,” said Richard Carreon, managing director and CEO of ImpediMed. “Our objective is to not only make L-Dex the standard of care in the clinical assessment of early stage lymphedema, but to explore its potential in other areas where a simple, sophisticated platform could accurately measure and monitor fluid levels, leading to better patient outcomes.”

Lymphedema is an accumulation of fluid in tissues that is commonly caused by abnormalities in the lymphatic system or due to removal or damage to a person's lymph nodes. Symptoms include swelling, recurrent cellulitis, loss of physical function, psychological stress, and a diminished qualify of life. It cannot be cured, and is typically managed through combined therapies of manual lymph drainage, multilayer bandaging, decongestive exercise, skin care, and long-term self-management.

Related Links:

ImpediMed



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.